Folinic acid adjunctive therapy cost effective in colorectal cancer

Author：  

Publisher： Adis International

ISSN： 1173-8324

Source： Inpharma, Vol.1, Iss.1394, 2003-01, pp. : 6-6

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Folinic acid adjunctive therapy cost effective in colorectal cancer

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 419, 2003-01 ,pp. : 5-5

Adis International

Access to resources Recommend Favorite

Oral tegafur/uracil + folinic acid in colorectal cancer

By  

Inpharma, Vol. 1, Iss. 1538, 2006-01 ,pp. : 17-17

Adis International

Access to resources Recommend Favorite

A Cost Comparison of Oral Tegafur Plus Uracil/Folinic Acid and Parenteral Fluorouracil for Colorectal Cancer in Canada

By Maroun J.A.  

PharmacoEconomics, Vol. 21, Iss. 14, 2003-01 ,pp. : 1039-1051

Adis International

Access to resources Recommend Favorite

Costs Incurred by Patients Undergoing Advanced Colorectal Cancer Therapy: A Comparison of Raltitrexed and Fluorouracil plus Folinic Acid

By Sculpher M.  

PharmacoEconomics, Vol. 17, Iss. 4, 2000-04 ,pp. : 361-370

Adis International

Access to resources Recommend Favorite

Multicenter, randomized phase II trial of bevacizumab plus folinic acid, fluorouracil, gemcitabine (FFG) versus bevacizumab plus folinic acid, fluorouracil, oxaliplatin (FOLFOX4) as first-line therapy for patients with advanced colorectal cancer

By Madajewicz Stefan  

Investigational New Drugs, Vol. 30, Iss. 2, 2012-04 ,pp. : 772-778

Springer Publishing Company

Access to resources Recommend Favorite